# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001880722 (5,42,44,45)

Office of origin: France

Date of International Registration:6 February 2025
Date of designation in the UK: 6 February 2025

Blue

International priority date claimed: 8 August 2024 (France) (5075489)

Class 5
  Medicines and pharmaceutical preparations for human use, in particular medicines and pharmaceutical preparations for treatment of diseases of the brain, the central nervous system and peripheral organs, cognitive disorders, neurodevelopmental disorders, psychiatric disorders, autism disorders, muscle disorders, dermatological disorders, human tissue deterioration, diabetes, obesity, addictions, and pathologies associated with cannabinoid use; medicines and pharmaceutical preparations targeting cannabinoid receptor type 1 (CB1) and type 2 (CB2); medicines and pharmaceutical preparations targeting G protein-coupled receptors (GPCRs); chemical, biochemical and molecular preparations and compositions for therapeutic and pharmaceutical use, in particular for treatment of diseases of the brain, the central nervous system and peripheral organs, cognitive disorders, neurodevelopmental disorders, psychiatric disorders, autism disorders, muscle disorders, dermatological disorders, human tissue deterioration, diabetes, obesity, addictions, and pathologies associated with cannabinoid use.
Class 42
  Evaluations and assessments in the scientific, pharmaceutical, pharmacological, biological, biotechnological, biochemical and clinical fields; research and development in the pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical and clinical fields; pre-clinical and clinical research; clinical trials; scientific research for medical purposes; design, testing and development of molecules and new molecular entities for therapeutic purposes; scientific laboratory work; chemical and biochemical analyses; providing scientific analyses related to pharmaceutical and medicated preparation design; testing of new pharmaceutical products for third parties; provision of information related to scientific research in pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical and clinical fields; providing and making available scientific information to third parties in the field of clinical and pre-clinical trials; providing information to third parties concerning results of clinical trials for medical and pharmaceutical products.
Class 44
  Medical services in the field of treatment of diseases of the brain, the central nervous system and peripheral organs, cognitive disorders, neurodevelopmental disorders, psychiatric disorders, autism disorders, muscle disorders, dermatological disorders, human tissue deterioration, diabetes, obesity, addictions, and pathologies associated with cannabinoid use; health care services; medical testing for the diagnosis and treatment of persons; medical screening, diagnostic and testing services; medical analysis services relating to the treatment of persons provided by medical laboratories; providing health information and advice, particularly with respect to treatment of diseases of the brain, the central nervous system and peripheral organs, cognitive disorders, neurodevelopmental disorders, psychiatric disorders, autism disorders, muscle disorders, dermatological disorders, human tissue deterioration, diabetes, obesity, addictions, and pathologies associated with cannabinoid use; evaluations and assessments in the medical field.
Class 45
  Licensing services regarding intellectual property rights in the pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical, molecular and clinical fields; licensing services for research and development in pharmaceutical, medical, pharmacological, biological, biotechnological, biochemical, molecular and clinical fields.

AELIS FARMA

Representative: Madame ALLARDON Juliette PLASSERAUD IP, 104 rue de Richelieu, F-75002 PARIS, FRANCE